Teva Investigational Site 14336(4.3 mi away)Contact
+60 other location
body mass index
major depressive disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult
patients with migraine and major depressive disorder (MDD)
The secondary objectives are to evaluate the efficacy of monthly 225 mg sc of fremanezumab in
adult patients with migraine and MDD on the reduction of MDD symptoms, responder rates in
monthly migraine days, improving quality of life, improving disability, and the safety and
tolerability of monthly 225 mg sc and quarterly 675 mg sc fremanezumab in adult patients with
migraine and MDD.
The total duration of patient participation in the study is planned to be approximately 28
Clinical Study Identifier
Teva Branded Pharmaceutical Products R&D, Inc.
Last Modified on
23 November 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.